H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) today and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors related to the promising developments in Tenaya Therapeutics’ clinical trials. The interim results from the MyPEAK-1 Phase 1b/2 study of TN-201, presented at the American College of Cardiology Scientific Sessions 2025, indicate positive progress in treating MYBPC3-associated hypertrophic cardiomyopathy (HCM). The gene therapy, designed to restore the MYBPC3 gene in heart muscle, has shown encouraging safety and efficacy data from the initial cohort of patients, with improvements in cardiac structure and function.
Furthermore, the safety profile of TN-401 remains consistent with other AAV gene therapies, with manageable side effects and no cardiac adverse events reported. The continued expression of TN-201 RNA and protein levels, along with improvements in heart failure symptoms among patients, supports the potential of this therapy. The ongoing dose escalation and the anticipation of further data releases in the coming months provide a strong foundation for Pantginis’s optimistic outlook on the stock.
According to TipRanks, Pantginis is an analyst with an average return of -15.0% and a 24.65% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Lexicon Pharmaceuticals.
In another report released on March 24, Canaccord Genuity also maintained a Buy rating on the stock with a $6.00 price target.